How Wegovy and Mounjaro Dosing Schedules Compare
Wegovy vs Mounjaro Dosing: Understanding Prescription Weight Loss Options
When comparing Wegovy vs Mounjaro dosing for prescription weight loss, the fundamental difference lies in their mechanisms and escalation schedules. Wegovy follows a structured 16-week dose escalation from 0.25mg to the maintenance dose of 2.4mg, whilst Mounjaro uses a different titration schedule starting at 2.5mg. Both treatments are prescription-only medicines requiring clinical assessment, but their dosing philosophies reflect their distinct pharmacological profiles.
The choice between these treatments depends on individual patient factors, tolerance, and prescriber recommendations. Wegovy's dosing schedule is specifically designed to minimise gastrointestinal side effects through gradual increases, whilst Mounjaro's dual receptor approach may offer different tolerability profiles. Both treatments are available from EverydayMeds following our comprehensive clinical assessment process, ensuring appropriate prescribing aligned with MHRA licensing requirements.
Wegovy vs Mounjaro Dosing: Pricing and Value Comparison
Understanding the cost implications when comparing Wegovy vs Mounjaro dosing helps inform treatment decisions. Wegovy pricing at EverydayMeds starts with 0.25mg at £79.99 (using code FIRST40), progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance 2.4mg (£209.99). Our Getting Started bundles provide convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, supporting the initial dose escalation phase.
Mounjaro follows different pricing due to its distinct dosing schedule and dual mechanism. Both treatments require ongoing commitment for sustained weight management, as clinical evidence demonstrates weight regain when treatment is discontinued. Returning customers can use code DOSE25 at checkout, whilst new customers benefit from FIRST40. The investment in prescription weight loss reflects the comprehensive clinical development, manufacturing standards, and regulatory oversight required for these advanced treatments.
Clinical Evidence Supporting Wegovy vs Mounjaro Dosing Protocols
The STEP clinical trial programme established Wegovy's dosing schedule through rigorous testing. In STEP 1, patients achieved approximately 15% average weight loss at 68 weeks when taking Wegovy alongside diet and exercise, compared to 2.4% with placebo. The dose escalation protocol was specifically designed based on this clinical evidence to optimise efficacy whilst managing tolerability.
Mounjaro's dosing schedule derives from the SURMOUNT trial programme, demonstrating its dual GIP and GLP-1 mechanism effectiveness. However, comparing trial weight loss percentages directly isn't appropriate due to different trial designs, populations, and endpoints. Both treatments represent significant advances in prescription weight management, with dosing schedules refined through extensive clinical development programmes overseen by the MHRA.
How Wegovy Works: Dosing and Mechanism for Weight Loss
Wegovy's dosing schedule supports its mechanism as a GLP-1 receptor agonist, mimicking natural fullness hormones to reduce appetite and promote satiety after smaller meals. The gradual dose escalation from 0.25mg to 2.4mg allows the body to adapt to increased GLP-1 activity, potentially reducing food cravings by working on brain appetite centres. Each weekly injection maintains consistent semaglutide levels, supporting sustained appetite control throughout the dosing interval. The 16-week escalation period ensures patients reach the therapeutic maintenance dose whilst minimising potential gastrointestinal effects. This carefully designed dosing protocol reflects years of clinical development to optimise both efficacy and patient experience. The once-weekly FlexTouch pen delivery system provides convenient administration, supporting long-term adherence to the prescribed dosing schedule.
Ordering Process: Wegovy vs Mounjaro Dosing Assessment
Accessing either treatment through EverydayMeds begins with our 3-minute online clinical assessment, covering medical history, current medications, and weight management goals relevant to both Wegovy vs Mounjaro dosing considerations. Our prescribers review applications within 3 working days (or 24 hours with express service), determining suitability based on MHRA licensing criteria including BMI ≥30 or ≥27 with weight-related comorbidity. Once approved, treatments are dispatched via next-day delivery using cold-chain temperature-controlled packaging to maintain medication integrity. Our GPhC-registered pharmacy ensures all prescribing meets UK regulatory standards, with ongoing support throughout your treatment journey. The assessment process considers individual factors that may influence dosing choices, ensuring personalised treatment recommendations aligned with clinical best practice.
Storage and Practical Considerations: Wegovy vs Mounjaro Dosing
Wegovy offers a storage advantage in the Wegovy vs Mounjaro dosing comparison, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day limit. Both treatments require refrigeration (2–8°C) before first use, but Wegovy's extended room temperature stability provides greater flexibility for travel and daily routine management. The FlexTouch pen design delivers precise dosing with clear dose confirmation, supporting accurate administration throughout the escalation schedule. Wegovy's dosing schedule requires maintaining each dose level for 4 weeks, allowing systematic progression whilst monitoring tolerance and response. This structured approach to dose escalation reflects clinical trial protocols that established optimal efficacy and safety profiles. Proper storage and adherence to the prescribed dosing schedule are essential for achieving the weight management outcomes demonstrated in clinical trials.
Personalised Treatment Selection: Wegovy vs Mounjaro Dosing Factors
The decision between Wegovy vs Mounjaro dosing ultimately depends on individual patient characteristics, medical history, and prescriber clinical judgement. Wegovy's GLP-1-only mechanism may suit patients who respond well to incretin-based therapies, whilst Mounjaro's dual GIP and GLP-1 approach offers an alternative mechanism for those requiring different therapeutic options. Some patients may have contraindications or preferences that influence treatment selection beyond simple dosing considerations.
Both treatments are available from EverydayMeds, allowing your prescriber to help determine which option aligns with your specific circumstances and weight management goals. The dosing flexibility within each treatment option enables personalisation based on individual tolerance and response. Rather than viewing this as a competition between treatments, the availability of both options represents advancing personalised medicine in weight management, with dosing protocols refined through extensive clinical development.
Starting Your Weight Management Journey: Wegovy vs Mounjaro Dosing Decision
Whether you choose Wegovy or Mounjaro dosing, beginning prescription weight loss treatment represents a significant commitment to long-term health improvement alongside lifestyle modifications. EverydayMeds supports both treatment pathways through our comprehensive service, from initial clinical assessment through ongoing prescription management and delivery. Our discount codes FIRST40 (new customers) and DOSE25 (returning customers) are applied at checkout, with Wegovy starting from £79.99 and various bundle options available for treatment continuity. The 3-minute assessment process considers factors relevant to both Wegovy vs Mounjaro dosing suitability, ensuring appropriate treatment selection based on individual circumstances. Both treatments are subject to MHRA additional monitoring (Black Triangle ▼) as part of ongoing safety surveillance, reflecting the commitment to patient safety in prescription weight management. Take the first step towards medically-supervised weight loss by completing our clinical assessment today, with next-day delivery available once your prescription is approved by our qualified prescribers.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
